(RTTNews) - Humacyte, Inc. (HUMA) on Thursday said it plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in the fourth quarter for its coronary tissue engineered vessel (CTEV) in coronary artery bypass grafting (CABG).
The company also announced the publication of new data in the Journal of the American College of Cardiology from a study evaluating CTEV as a coronary artery bypass graft conduit in a non-human primate model.
Humacyte said all implanted CTEVs remained patent throughout the six-month study and recellularized with host cells, suggesting that CTEV could serve as a durable alternative conduit for CABG.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
